Vontobel Holding Ltd. I Teos Therapeutics, Inc. Transaction History

Vontobel Holding Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jun 03, 2024	BUY	$8.57 - $11.06 $556,887 - $718,689	64,981 Added 41.9%	220,056 $2.41 Million
Q4 2023 Jan 29, 2024	BUY	$8.57 - $11.06 $556,887 - $718,689	64,981 Added 41.9%	220,056 $2.41 Million
Q3 2023 Jun 03, 2024	BUY	$10.95 - $14.6 $93,064 - $124,085	8,499 Added 5.8%	155,075 $1.7 Million
Q3 2023 Oct 10, 2023	BUY	$10.95 - $14.6 $93,064 - $124,085	8,499 Added 5.8%	155,075 $1.7 Million
Q2 2023 Jun 03, 2024	BUY	$12.93 - $18.05 $752,564 - $1.05 Million	58,203 Added 65.86%	146,576 $1.94 Million
Q2 2023 Jul 24, 2023	BUY	$12.93 - $18.05 $752,564 - $1.05 Million	58,203 Added 65.86%	146,576 $1.94 Million
Q1 2023 Jun 03, 2024	BUY	$13.02 - $22.62 $1.15 Million - $2 Million	88,373 New	88,373 $1.2 Million
Q1 2023 Apr 12, 2023	BUY	$13.02 - $22.62 $398,555 - $692,420	30,611 Added 53.0%	88,373 $1.2 Million
Q4 2022 Feb 14, 2023	BUY	$17.77 - $21.6 $1.03 Million - $1.25 Million	57,762 New	57,762 $1.13 Million

165

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $293M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.